Restricted accessResearch articleFirst published online 2012-3
Effect of Telmisartan and Ramipril on Atrial Fibrillation Recurrence and Severity in Hypertensive Patients With Metabolic Syndrome and Recurrent Symptomatic Paroxysmal and Persistent Atrial Fibrillation
This study evaluated the effect of telmisartan, ramipril, and amlodipine on atrial fibrillation (AF) recurrence and severity in hypertensive patients with metabolic syndrome. A total of 391 hypertensive outpatients with metabolic syndrome, in sinus rhythm but with at least 2 episodes of AF in the previous 6 months were randomized to telmisartan, ramipril, or amlodipine for 1 year. At the first AF, ventricular rate (VR) and plasma cardiac troponin I (TnI) were evaluated. P-wave dispersion (PWD) and procollagen type I carboxy-terminal peptide (PIP) were evaluated before and after 12 months of treatment. Systolic blood pressure (SBP) and diastolic blood pressure (DBP) were similarly and significantly reduced by all treatments (P < .001). In all, 49% of patients treated with amlodipine had a recurrence of AF as did 25.5% of patients with ramipril and 12.9% of patients with telmisartan (P < .01 vs amlodipine and P < .05 vs ramipril). Ventricular rate and TnI at the first AF recurrence were significantly lower with telmisartan and ramipril than with amlodipine. P-wave dispersion was reduced by ramipril (−5.1 ms, P < .05) and even more by telmisartan (−11 ms, P < .01). Telmisartan and ramipril induced a similar PIP reduction (−52.8 and −49.8 µg/L, respectively, P < .01). These findings suggested that in these patients telmisartan was more effective than ramipril in reducing AF recurrence and severity as well as in improving PWD, despite a similar BP reduction and a similar improvement in cardiac fibrosis. This could be related to a specific effect of telmisartan on atrial electric remodeling.
KannelWBWolfPABenjaminEJLevyD.Prevalence, incidence, prognosis and predisposing conditions for atrial fibrillation: population-based estimates. Am J Cardiol. 1998;82(8A):2N–9N.
2.
VidailletHGranadaJFChyoiPH. A population-based study of mortality among patients with atrial fibrillation or flutter. Am J Med. 2002;113(5):365–370.
3.
UmetaniKKodamaYNakamuraT. High prevalence of paroxysmal atrial fibrillation and/or atrial flutter in metabolic syndrome. Circ J. 2007;71(2):252–255.
4.
WatanabeHTanabeNWatanabeT. Metabolic syndrome and risk of development of atrial fibrillation. The Niigata Preventive Medicine Study. Circulation. 2008;117(10):1255–1260.
5.
. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel,ATP III). JAMA. 2001;285(19):2486–2497.
6.
GrundySMCleemanJIDanielsSR. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung and Blood Institute Scientific Statement. Circulation. 2005;112(17):2735–2752.
7.
MohavedMRHashemzadehMJamalMM.Diabetes mellitus is a strong, independent risk for atrial fibrillation and flutter in addition to other cardiovascular disease. Int J Cardiol. 2005;105(3):315–318.
8.
DublinSFrenchBGlazerNL. Risk of new-onset atrial fibrillation in relation to body mass index. Arch Int Med. 2006;166(21):2322–2328.
9.
EngelmannMDHSvendsenJH.Inflammation in the genesis and perpetuation of atrial fibrillation. Eur Heart J. 2005;26(20):2083–2092.
10.
KorantzopoulosPKolettisTMGalarisDGoudevenosJA.The role of oxidative stress in the pathogenesis and perpetuation of atrial fibrillation. Int J Cardiol. 2007;115(2):135–143.
11.
LiDFarehSLeungTKNattelS.Promotion of atrial fibrillation by heart failure in dogs: atrial remodeling of a different sort. Circulation. 1999;100(1):87–95.
12.
NattelSShiroshita-TakeshitaACardinSPelletierP.Mechanisms of atrial remodelling and clinical relevance. Curr Opin Cardiol. 2005;20(1):21–25.
13.
BoschRFZengXGrammerJBPropovicKMewisCKuhlkampV.Ionic mechanisms of electrical remodelling in human atrial fibrillation. Cardiovasc Res. 1999;44(1):121–131.
14.
BoldtAWetzelULauschkeJ. Fibrosis in left atrial tissue of patients with atrial fibrillation with and without underlying mitral valve disease. Heart. 2004;90(4):400–405.
15.
SerraJLBenderskyM.Atrial fibrillation and the renin-angiotensin system. Ther Adv Cardiovasc Dis. 2008;2(3):215–223.
16.
Mc EwanPEGrayGASherryLWebbDJKenyonCJ.Differential effects of angiotensin II on cardiac cell proliferation and intramyocardial perivascular fibrosis in vivo. Circulation. 1998;98(24):2765–2773.
17.
YuHGaoJWangH. Effects of the renin-angiotensin system on the current I (to) in epicardial and endocardial ventricular myocytes from the canine heart. Circ Res. 2000;86(10):1062–1068.
18.
GoetteAArndtMRockenC. Regulation of angiotensin II receptor subtypes during atrial fibrillation in humans. Circulation. 2000;101(23):2678–2681.
19.
TsaiCTLaiLPLinJL. Renin-angiotensin system gene polymorphisms and atrial fibrillation. Circulation. 2004;109(13):1640–1646.
20.
LiDShinagawaKPangL. Effects of angiotensin-converting enzyme inhibition on the development of the atrial fibrillation substrate in dogs with ventricular tachypacing-induced congestive heart failure. Circulation. 2001;104(21):2608–2614.
21.
HealeyJSBaranchuckACrystalEGarfinkleMYusufSConnollySJ.Prevention of atrial fibrillation with angiotensin converting enzyme inhibitors and angiotensin receptor blockers:a meta-analysis. J Am Coll Cardiol. 2005;45(11):1832–1839.
22.
KishlayAMoosesANHeeTTMohiuddinSM.Meta-analysis: inhibition of renin-angiotensin system prevents new-onset atrial fibrillation. Am Heart J. 2006;152(2):217–222.
23.
MadridAHBuenoMGRebolloJM. Use of irbesartan to maintain sinus rhythm in patients with lon lasting persistent atrial fibrillation: a prospective and randomized study. Circulation. 2002;106(3):331–336.
24.
UengKCTsaiTPYuWC. Use of enalapril to facilitate sinus rhythm maintenance after external cardioversion of long-standing persistent atrial fibrillation. Results of a prospective and controlled study. Eur Heart J. 2003;24(23):2090–2098.
25.
AnneWWillemsRVan der MerweNVan de WerfFEctorHHeidbuchelH.Atrial fibrillation after radiofrequency ablation of atrial flutter: preventive effect of angiotensin converting enzyme inhibitors, angiotensin II receptor blockers and diuretics. Heart. 2004;90(9):1025–1030.
26.
YinYDalalDLiuZ. Prospective randomized study comparing amiodarone vs amiodarone plus losartan vs amiodarone plus perindopril for the prevention of atrial fibrillation recurrence in patients with lone paroxysmal atrial fibrillation. Eur Heart J. 2006;27(15):1841–1846.
27.
FogariRMugelliniADestroM. Losartan and prevention of atrial fibrillation recurrence in hypertensive patients. J Cardiovasc Pharmacol. 2006;47(1):46–50.
28.
The GISSI-AF Investigators. Valsartan for prevention of recurrent atrial fibrillation. N Engl J Med. 2009;360(16):1606–1617.
29.
FogariRDerosaGFerrariI. Effect of valsartan and ramipril on atrial fibrillation recurrence and P wave dispersion in hypertensive patients with recurrent symptomatic lone atrial fibrillation. Am J Hypertens. 2008;21(9):1034–1039.
30.
The ONTARGET Investigators. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med. 2008;358(15):1547–1559.
31.
DilaverisPEGialafosEJChrissosD. Detection of hypertensive patients at risk for paroxysmal atrial fibrillation during sinus rhythm by computer-assisted P-wave analysis. J Hypertens. 1999;17(10):1463–1470.
32.
DilaverisPEGialafosEJ.P-wave dispersion:a novel predictor of paroxysmal atrial fibrillation. Ann Noninvas Electrocardiol. 2001;6(2):159–165.
33.
DiezJLaviadesCMayorGGilMUMonrealI.Increased serum concentrations of procollagen peptides in essential hypertension relation to cardiac alterations. Circulation. 1995;91(5):1450–1456.
34.
LopezBGonzalesAVaroNLaviadesCQuerejetaRDiezJ.Biochemical assessment of myocardial fibrosis in hypertensive heart disease. Hypertension. 2001;38(5):1222–1226.
35.
RisteliJElomaaINiemiSNovamoARisteliL.Radioimmunoassay for the pyridinoline cross-linked carboxyterminal telo peptide of type I collagen: a new serum marker of collagen degradation. Clin Chem. 1993;39(4):635–640.
36.
LaviadesCVaroNFernandezJ. Abnormalities of the extracellular degradation of collagen type I in essential hypertension. Circulation. 1998;98(6):535–540.
37.
MeikkoJNiemiSRisteliJ.Radioimmunoassay of the carboxyterminal pro peptide of human type I procollagen. Clin Chem. 1990;36(7):1328–1332.
38.
FesmireFMFesmireCE.Improved identification of acute coronary syndrome with second generation cardiac troponin I assay. J Emerg Med. 2002;22(2):147–152.
39.
ZellwegerMJSchaerBACronTAPfistereMOsswaldS.Elevated troponin levels in the absence of coronary artery disease after supraventricular tachycardia. Swiss Med Wkly. 2003;133(31-32):439–441.
40.
KanjwalKImranNGrubbBKanjwalY.Troponin elevation in patients with various tachycardias and normal epicardial coronaries. Indian Pacing Electrophysiol J. 2008;8(3):172–174.
41.
PatanèSMarteFDi BellaG.Abnormal troponin I levels after supraventricular tachicardia. Int J Cardiol. 2009;132(2):e57–e59.
42.
AksnesTAFlaaAStrandAKjeldsenSE.Prevention of atrial fibrillation in hypertension. Curr Hypertens Rep. 2000;10(3):175–181.
43.
SoranHZiglamHAl-NajjarMYounisN.The role of the renin angiotensin system blocking in the management of atrial fibrillation. Acta Cardiol. 2008;63(4):457–467.
44.
AnisRR.Role of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in the management of atrial fibrillation. Exp Clin Cardiol. 2009;14(1):e1–e7.
45.
CaballeroRDelponEValenzuelaCLongobardoMTamargoJ.Losartan and its metabolita E3174 modify cardiac delayed rectifier K+ currents. Circulation. 2002;101(10):1199–1205.
46.
DelponECaballeroRGomezRNunezLTamargoJ.Angiotensin II, Angiotensin II antagonists and spironolactone and their modulation of cardiac repolarization. Trends Pharmacol Sci. 2005;26(3):155–161.
47.
LiYLiWXueJHanWYangSGuH.Effects of losartan on acute atrial electrical remodeling. Chin Med J. 2004;117(5):643–646.
48.
CiullaMMPaliottiREspositoA. Different effects of antihypertensive therapies based on losartan or atenolol on ultrasound and biochemical markers of myocardial fibrosis: results of randomized trial. Circulation. 2004;110(5):552–557.
49.
BoldtASchollAGarbadeJ. Ace-inhibitor treatment attenuates atrial structural remodeling in patients with lone chronic atrial fibrillation. Basic Res Cardiol. 2006;101(3):261–267.
50.
ShiYLiDTardifJCNattelS.Enalapril effects on atrial remodeling and atrial fibrillation in experimental congestive heart failure. Cardiovasc Res. 2002;54(2):456–461.
51.
GerdtzEOikarinenLPalmieriV. Losartan Intervention For Endpoint Reduction in Hypertension (LIFE) Study. Correlates of left atrial size in hypertensive patients with left ventricular hypertrophy: the Losartan Intervention for End-point reduction in hypertension (LIFE) study. Hypertension. 2002;39(3):739–743.
52.
TuDNLiaoYHZouAR. Electropharmacological properties of telmisartan in blocking hKv1.5 and HERG potassium channels espressed on Xenopus laevis oocytes. Acta Pharmacol Sin. 2008;29(8):913–922.
53.
CelikTIyisoyAKursakliogluH. The comparative effectsof telmisartan and ramipril on P-wave dispersion in hypertensive patients: a randomized clinical study. Clin Cardiol. 2005;28(6):298–302.
54.
WeberKT.Fibrosis and hypertensive heart disease. Curr Opin Cardiol. 2000;15(4):264–272.
55.
KallergisEMManiosEGKanoupakisEM. Extracellular matrix alterations in patients with paroxysmal and persistent atrial fibrillation. J Am Coll Cardiol. 2008;52(3):211–215.
56.
YamagishiSTakeuchiM.Telmisartan is a promising cardiometabolic sartan, due to its unique PPAR-gamma inducing property. Med Hypotheses. 2005;64(3):476–478.
57.
TakanoHHasegawaHZouYKomuroI.Pleiotropic actions of PPAR gamma activators thiazolinediones in cardiovascular disease. Curr Pharm Des. 2004;10(22):2779–2786.
58.
ShimanoMTsujiYIndenY. Pioglitazone, a peroxisome proliferator-activated receptor-gamma activator, attenuates atrial fibrosis and atrial fibrillation promotion in rabbits with congestive heart failure. Heart Rhythm. 2008;5(3):451–459.
59.
YamagishiSIMatsuiTNakamuraK.Possible molecular mechanisms by which angiotensin type 1 receptor blockers (ARBs) prevent the development of atrial fibrillation in insulin resistant patients. Horm Metab Res. 2008;40(9):640–644.
60.
BensonSCPershadsinghHAHoCI. Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPAR-gamma modulating activity. Hypertension. 2004;43(5):993–1002.
61.
The Telmisartan Randomised AssessmeNt Study in ACE iNtolerant subjects with cardiovascular Disease (TRANSCEND) Investigators. Effect of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomized controlled trial. Lancet. 2008;372(9644):1174–1183.
62.
KakutaHSudohKSasamataMYamagishiS.Telmisartan has the strongest binding affinity to angiotensin type I receptor: comparison with other angiotensin II type 1 receptor blockers. Int J Clin Pharmacol Res. 2005;25(1):41–46.
